Aviva Capital Partners (“ACP”), Aviva’s in-house capital unit that invests in a range of infrastructure and real estate projects, and mixed-use developer Socius have unveiled plans for a new £1 billion development to create the world’s leading centre for cancer research and treatment in Sutton, London. 

A planning application has been submitted to London Borough of Sutton for the development which will be delivered on a 12-acre site at the London Cancer Hub, adjacent to The Institute of Cancer Research, London, one of the world’s leading cancer research organisations, and The Royal Marsden NHS Foundation Trust’s Sutton site, Europe’s leading centre for cancer treatment.

Working with London Borough of Sutton as the landowner, ACP and Socius plan to deliver c. 1 million sq ft of state-of-the-art research and laboratory space in order to bring leading life sciences companies together with academic researchers and clinicians to drive innovation in cancer research.

The development will support 3,000 new jobs, the majority of which will be in high-skilled R&D and small-scale manufacturing related to life sciences. According to an analysis by London Borough of Sutton, by the time the development is complete the London Cancer Hub will support 13,000 jobs in total and contribute an estimated £1.2 billion per year (Gross Value Added) to the UK economy.

The new buildings will range from large-scale facilities for global pharmaceutical and life sciences companies through to smaller, flexible lab and incubator spaces for start-ups, with the capacity to accommodate wet labs, Goo…